Results 111 to 120 of about 969,782 (213)

CaMKII suppresses proteotoxicity by phosphorylating BAG3 in response to proteasomal dysfunction

EMBO Reports
Protein quality control serves as the primary defense mechanism for cells against proteotoxicity induced by proteasome dysfunction. While cells can limit the build-up of ubiquitinated misfolded proteins during proteasome inhibition, the precise mechanism
Chenliang Zhang, Huanji Xu, Qiulin Tang, Yichun Duan, Hongwei Xia, Huixi Huang, Di Ye, Feng Bi   +7 more
doaj   +1 more source

Molecular targeted therapy: A new avenue in glioblastoma treatment. [PDF]

Oncol Lett, 2023
El Atat O, Naser R, Abdelkhalek M, Habib RA, El Sibai M.   +4 more
europepmc   +1 more source

Recent advances in immunotherapy and molecular targeted therapy for gastric cancer. [PDF]

Future Sci OA, 2023
Yoshinami Y, Shoji H.
europepmc   +1 more source

Molecular Targets for Breast Cancer Therapy

Biomolecules
Breast cancer is by far the most common cancer in women, and for a while, it surpassed lung cancer as the most diagnosed cancer, regardless of gender, in 2020 [...]
openaire   +4 more sources

Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer-A Step before Anakoinosis-Based Personalized Treatment. [PDF]

Cancers (Basel), 2023
Kleszcz R.
europepmc   +1 more source

Targeted Molecular Therapy [PDF]

, 2020
openaire   +1 more source

Synergistic Phototherapy-Molecular Targeted Therapy Combined with Tumor Exosome Nanoparticles for Oral Squamous Cell Carcinoma Treatment. [PDF]

Pharmaceutics, 2023
Li M, Yin S, Xu A, Kang L, Ma Z, Liu F, Yang T, Sun P, Tang Y.   +8 more
europepmc   +1 more source

Pathology confronts molecular targeted therapies [PDF]

Nature Clinical Practice Oncology, 2006
openaire   +2 more sources

Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma. [PDF]

Cancer Innov, 2023
Wang Y, Li S, Peng Y, Ma W, Wang Y, Li W.   +5 more
europepmc   +1 more source

Prognosis Prediction of CRAFITY Score in HCC Undergoing TACE Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapy. [PDF]

J Hepatocell Carcinoma, 2023
Hu ZX, Xu XY, Wang Z, Huang JT, Li WC, Zhang S, Shen J, Zhong BY, Zhu XL.   +8 more
europepmc   +1 more source